Methodological issues associated with preclinical drug development and increased placebo effects in schizophrenia clinical trials

被引：0

作者：

Brown, Matt A. ^{[1
]}

Bishnoi, Ram J. ^{[1
]}

Dholakia, Sara ^{[1
]}

Velligan, Dawn I. ^{[1
]}

机构：

[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7703 Floyd Curl Dr,Mail Stop 7797, San Antonio, TX 78229 USA

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 04期

关键词：

treatment efficacy; methodological issues; pharmacology; placebo effect; drug development; schizophrenia; preclinical; clinical trials; CONSENSUS COGNITIVE BATTERY; IMPROVING SIGNAL-DETECTION; ANIMAL-MODELS; NEGATIVE SYMPTOMS; ANTIPSYCHOTIC-DRUGS; PHARMACOLOGICAL-TREATMENT; ATYPICAL ANTIPSYCHOTICS; PSYCHIATRIC-DISORDERS; ADJUNCTIVE TREATMENT; DROPOUT RATES;

D O I：

10.1586/17512433.2016.1135734

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Recent failures to detect efficacy in clinical trials investigating pharmacological treatments for schizophrenia raise concerns regarding the potential contribution of methodological shortcomings to this research. This review provides an examination of two key methodological issues currently suspected of playing a role in hampering schizophrenia drug development; 1) limitations on the translational utility of preclinical development models, and 2) methodological challenges posed by increased placebo effects. Recommendations for strategies to address these methodological issues are addressed.

引用

页码：591 / 604

页数：14

共 50 条

[1] Placebo response in clinical trials with schizophrenia patients
Kinon, Bruce J.
Potts, Alison J.
Watson, Susan B.
CURRENT OPINION IN PSYCHIATRY, 2011, 24 (02) : 107 - 113
[2] Methodological Issues and Publication Bias in Reporting Clinical Trials in Schizophrenia
Bowcut, Jana
Levi, Linda
Livneh, Ortal
Davis, John M.
Weiser, Mark
NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S342 - S342
[3] Methodological issues associated with clinical trials in neuropathic pain
Gilron, Ian
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (11) : 1399 - 1402
[4] Conceptual and Methodological Issues in the Design of Clinical Trials of Antipsychotics for the Treatment of Schizophrenia
William G. Honer
Allen E. Thornton
Megan Sherwood
G. William MacEwan
Tom S. Ehmann
Richard Williams
Lili C. Kopala
Ric Procyshyn
Alasdair M. Barr
CNS Drugs, 2007, 21 : 699 - 714
[5] Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?
Alphs, Larry
Benedetti, Fabrizio
Fleischhacker, W. Wolfgang
Kane, John M.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 (07) : 1003 - 1014
[6] Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications
Green, MF
Braff, DL
BIOLOGICAL PSYCHIATRY, 2001, 49 (04) : 374 - 384
[7] Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia
Marder, Stephen R.
Alphs, Larry
Anghelescu, Ion-George
Arango, Celso
Barnes, Thomas R. E.
Caers, Ivo
Daniel, David G.
Dunayevich, Eduardo
Fleischhacker, W. Wolfgang
Garibaldi, George
Green, Michael F.
Harvey, Philip D.
Kahn, Rene S.
Kane, John M.
Keefe, Richard S. E.
Kinon, Bruce
Leucht, Stefan
Lindenmayer, Jean-Pierre
Malhotra, Anil K.
Stauffer, Virginia
Umbricht, Daniel
Wesnes, Keith
Kapur, Shitij
Rabinowitz, Jonathan
SCHIZOPHRENIA RESEARCH, 2013, 150 (2-3) : 328 - 333
[8] Can preclinical drug development help to predict adverse events in clinical trials?
Chi, Lap Hing
Burrows, Allan D.
Anderson, Robin L.
DRUG DISCOVERY TODAY, 2022, 27 (01) : 257 - 268
[9] Modelling and simulation of placebo effect: application to drug development in schizophrenia
Reddy, Venkatesh Pilla
Kozielska, Magdalena
de Greef, Rik
Vermeulen, An
Proost, Johannes H.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 (03) : 377 - 388
[10] Methodological issues in current antipsychotic drug trials
Leucht, Stefan
Heres, Stephan
Hamann, Johannes
Kane, John M.
SCHIZOPHRENIA BULLETIN, 2008, 34 (02) : 275 - 285

← 1 2 3 4 5 →